JPRN-UMIN000017014已完成未知
A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects with Type 2 Diabetes Mellitus - A Phase 2b Study of Bexagliflozin Tablets on HbA1c in Subjects with Type 2 Diabetes Mellitus
Theracos, Sub., LLC0 个研究点目标入组 320 人开始时间: 2015年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.A diagnosis of type 1 diabetes mellitus or maturity onset diabetes of the young (MODY) 2.Current use of parenteral therapy for treatment of diabetes (insulin or glucagon-like peptide-1 (GLP-1) receptor agonist therapy) 3.Hemoglobinopathy or carrier status for hemoglobin alleles that affect HbA1c measurement 4.Genitourinary tract infection (e.g. urinary tract infection, vaginitis, balanitis) within 6 weeks of screening or history of =>genitourinary infections requiring treatment within 6 months of screening 5.Estimated glomerular filtration rate (eGFR), as calculated by the modification of diet in renal disease study equation (MDRD), < 60 mL/min/1.73 m2 at screening (Appendix 2) 6.Uncontrolled hypertension (average of two sitting measurements of systolic blood pressure >160 mmHg or diastolic blood pressure > 95 mmHg) at screening 7.History of New York Heart Association (NYHA) Class 4 heart failure within 3 months of screening 8.History of MI, unstable angina, stroke, or hospitalization for heart failure within 3 months of screening 9.History of treatment with an investigational drug within 30 days or within 7 half lives of the investigational drug, whichever is longer 10.Previous treatment with bexagliflozin or EGT0001474 11.Currently or within 6 months of taking any SGLT2 inhibitors from screening 12.ALT or AST => 2.5 x upper limit of normal (ULN) or total bilirubin=> 1.5 x ULN with the exception of isolated Gilbert's syndrome at screening 13.Exhibiting fasting plasma glucose=> 250 mg/dL (13.9 mmol/L) on two or more consecutive days prior to randomization or exhibiting severe clinical signs or symptoms of hyperglycemia during the washout or run-in periods, including weight loss, blurred vision, increased thirst, or increased urination, or fatigue 14.FPG =>250 mg/dL at randomization 15.Prior renal transplantation or evidence of nephrotic syndrome, defined as a urine albumin-to-creatinine ratio (UACR) > 2000 mg/g at screening
研究者
相似试验
进行中（未招募）
1 期
A study to test ABI-H0731 with Entecavir to treat patients with Chronic Hepatitis BChronic Hepatitis BEUCTR2018-002042-36-GBAssembly Biosciences20
进行中（未招募）
不适用
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's DiseaseCrohn’s DiseaseMedDRA version: 17.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-004399-42-Outside-EU/EEACB Japan Co., Ltd.100
进行中（未招募）
1 期
A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-000244-24-CZPfizer Ltd.460
进行中（未招募）
不适用
A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.EUCTR2004-000244-24-ITPFIZER
进行中（未招募）
1 期
A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-000244-24-ESPfizer, S.A.460